Fig. 5: Signaling analysis upon afatinib/tozasertib co-treatment in KRAS mutated LUAD cells.
From: KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
a qRT-PCR for designated genes in cell lines treated with the indicated agents (37 nM each compound (PULM21); 111 nM each compound (MML884, MML416, KP)) for 96 h. Data are normalized against 28S and presented as mean values ± SEM (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. not significant (One-way ANOVA with subsequent Bonferroni posttest). b Cells treated with the indicated agents (37 nM each compound (PULM21); 111 nM each compound (MML416, KP)) for 96 hours were assessed by immunoblots. ß-Actin and HSC70 served as a loading control.
